Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Molecular Partners Ag (MOLN) over the last 5 years, with Dec 2024 value amounting to $72.6 million.

  • Molecular Partners Ag's Cash & Equivalents rose 35.66% to $102,955 in Q3 2025 from the same period last year, while for Sep 2025 it was $102,955, marking a year-over-year increase of 35.66%. This contributed to the annual value of $72.6 million for FY2024, which is 96778.94% up from last year.
  • According to the latest figures from FY2024, Molecular Partners Ag's Cash & Equivalents is $72.6 million, which was up 96,778.94% from $74,945 recorded in FY2023.
  • Molecular Partners Ag's Cash & Equivalents' 5-year high stood at $147.9 million during FY2020, with a 5-year trough of $74,945 in FY2023.
  • Over the past 3 years, Molecular Partners Ag's median Cash & Equivalents value was $91,290 (recorded in 2022), while the average stood at $24.3 million.
  • In the last 5 years, Molecular Partners Ag's Cash & Equivalents slumped by 99.95% in 2021 and then surged by 96,778.94% in 2024.
  • Yearly analysis of 5 years shows Molecular Partners Ag's Cash & Equivalents stood at $147.9 million in 2020, then crashed by 99.95% to $77,881 in 2021, then rose by 17.22% to $91,290 in 2022, then fell by 17.90% to $74,945 in 2023, then skyrocketed by 96,778.94% to $72.6 million in 2024.